Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol | Zendy

Kausik K. Ray | Zendy; Ulf Landmesser | Zendy; Lawrence A. Leiter | Zendy; David Kallend | Zendy; Robert Dufour | Zendy; Mahir Karakas | Zendy; Tim N. Hall | Zendy; Roland P.T. Troquay | Zendy; Traci Turner | Zendy; Frank L.J. Visseren | Zendy; Peter Wijngaard | Zendy; R. Scott Wright | Zendy; John J.P. Kastelein | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol

Author(s) -

Kausik K. Ray,

Ulf Landmesser,

Lawrence A. Leiter,

David Kallend,

Robert Dufour,

Mahir Karakas,

Tim N. Hall,

Roland P.T. Troquay,

Traci Turner,

Frank L.J. Visseren,

Peter Wijngaard,

R. Scott Wright,

John J.P. Kastelein

Publication year - 2017

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1615758

Subject(s) - medicine , pcsk9 , placebo , cholesterol , regimen , randomization , endocrinology , clinical endpoint , lipoprotein , gastroenterology , randomized controlled trial , ldl receptor , alternative medicine , pathology

In a previous study, a single injection of inclisiran, a chemically synthesized small interfering RNA designed to target PCSK9 messenger RNA, was found to produce sustained reductions in low-density lipoprotein (LDL) cholesterol levels over the course of 84 days in healthy volunteers.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research